<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8756EB88-F187-487C-A54E-9210F5ECAFA6"><gtr:id>8756EB88-F187-487C-A54E-9210F5ECAFA6</gtr:id><gtr:name>MRC Anatomical Neuropharmacology Unit</gtr:name><gtr:address><gtr:line1>Mansfield Road</gtr:line1><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 3TH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8756EB88-F187-487C-A54E-9210F5ECAFA6"><gtr:id>8756EB88-F187-487C-A54E-9210F5ECAFA6</gtr:id><gtr:name>MRC Anatomical Neuropharmacology Unit</gtr:name><gtr:address><gtr:line1>Mansfield Road</gtr:line1><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 3TH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/83307C90-06EC-428F-9F81-79755DB34BCC"><gtr:id>83307C90-06EC-428F-9F81-79755DB34BCC</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>McIlhinney</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U138162357"><gtr:id>E7B0ED4C-3730-4CF5-BF92-87885662A871</gtr:id><gtr:title>Establishment and trafficking of signalling complexes by Glutamate and GABA-B receptors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U138162357</gtr:grantReference><gtr:abstractText>In the human brain, nerve cells are activated by the amino acid, glutamic acid, whereas a related chemical, gamma-amino butyric acid (GABA) is responsible for the inhibition of the activity of nerve cells. These effects are mediated by different receptor proteins that bind these chemical messengers specifically, and inform the cell about their presence in the extracellular space in the brain. The rapid responses to binding of these chemicals are caused by the opening of ion channels, whilst slower responses are the result of activating different glutamate and GABA receptors, which leads to the production of secondary messengers inside the cell. Over-stimulation, or failure to respond, of any of these receptors can lead to a variety of pathological conditions. Therefore, these receptors are important targets for therapeutic intervention in diseases such as epilepsy, anxiety, depression and neuronal death following strokes. Our research program is designed to increase our understanding of these receptors in terms of their structure, and their interactions with other proteins that can modulate their function and targeting on the surface of nerve cells. We are therefore characterising the structure of the N-methyl-D-aspartate receptor (a subtype of the glutamate receptors) and the protein interactions of three second messenger coupled receptors, the metabotropic glutamate receptor type 1a/b, and the GABAB receptor.</gtr:abstractText><gtr:technicalSummary>Glutamate receptors mediate most of the fast excitatory neurotransmission in the central nervous system, whilst gamma-amino butyric acid (GABA) receptors mediate inhibitory neurotransmission. Whilst both of these receptors utilize ion channels for fast signalling, they also have second messenger-coupled receptors that modulate neurotransmission on longer time scales. The ion channels opened by glutamate include the N-methyl-D aspartate (NMDA) receptor, which has an important role in learning and memory. The second messenger coupled receptors for glutamate (mGluRs) and GABA (GABAB receptor are also important therapeutic targets for a range of pathological conditions, including epilepsy, neuro-excitotoxicity, anxiety and depression. Understanding the structure and function of these receptors is, therefore, extremely important, especially as it has become apparent that they function in large molecular complexes, which can modulate their responses. This project is designed to identify the components of these complexes for the GABAB receptor as well as examining the intracellular trafficking and assembly of these receptors.||The NMDA receptor is functional only when two subunits, an NR1 and NR2 subunit, combine to form an oligomeric ion channel, the precise stoichiometry of which is currently unclear. We have shown that the assembly of the receptor requires the stable production of the NR1 subunit as a dimer, which then acts to encourage the folding and assembly of the other NMDA receptor subunits into a functional receptor. Currently we are using bi-molecular fluorescence complementation to examine the preferred pathway for receptor subunit assembly.||Previous work from the laboratory, in collaboration with Dr. Julia White of Glaxo Smith Kline, has already identified novel proteins that interact with the newly described GABAB receptor. Work continues to characterize these, and has been expanded to take account of our recent discovery that a substantial proportion of this receptor is present in lipid domains enriched in cholesterol and sphingolipids in the rat brain. Currently we are examining the role of these domains in determining GABAB function, and examining the consequences for GABAB pharmacology and signalling. In addition we are examining the mechanisms by which the receptor becomes localized to the lipid rafts.||The methods we have developed to examine receptor assembly have also been applied, in collaboration with Dr Derek Blake (Dept. Pharmacology, Oxford) in the study of the genetic conditions caused by mutations in two proteins, namely fukitin related protein and epsilon-sarcoglycan. Mutations in these proteins cause dystonias, and central nervous system deficits. These studies have revealed that the mutations cause incorrect trafficking of the proteins.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>990194</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GABAB receptor research</gtr:description><gtr:id>D4DFE382-6E0B-44A4-827A-A681488EE09C</gtr:id><gtr:impact>Several publications, and a consultancy with GSK for three years. Ongoing work from this collaboration formed part of our successful 2008 quinquennial review proposals.</gtr:impact><gtr:outcomeId>E5354461295-1</gtr:outcomeId><gtr:partnerContribution>Cell lines, cDNA clones, antibodies and other reagents. Access to instrumentation and analysis or proteomic screens</gtr:partnerContribution><gtr:piContribution>Analysis of receptor interacting proteins, and their consequences.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Arts Science Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>D33A3DE1-0974-426F-A7B6-D5BDBAAD8E6C</gtr:id><gtr:impact>Acted as one of the scientists in residence at an Arts Science Workshop in Reading.

None</gtr:impact><gtr:outcomeId>00CDB9A23A6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>434E4E33-F1FF-4325-974F-6E8E0759B92A</gtr:id><gtr:impact>Presented a talk entitled &amp;quot;Lipid Rafts as platforms for GABAB receptor function&amp;quot; at the IBRO International Congress of Neuroscience, Melbourne Australia

None</gtr:impact><gtr:outcomeId>750F0A80183</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2391F539-B440-47C9-ADED-F08E7890764F</gtr:id><gtr:impact>Annual school science day in Unit where we exhibit our work and encourage discussion of science as a subject and career.

Positive feedback from teachers and students.</gtr:impact><gtr:outcomeId>BAF8A32A38D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>821C9D01-7E28-488B-8CE6-B701627FAB26</gtr:id><gtr:impact>Manned stand for MRC at theCheltenham Science Festival

Very Positive feedback form public</gtr:impact><gtr:outcomeId>CBF29B2D00E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science week in Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>3A4F98B9-0F42-48D5-88F7-BADD2E5A6FFF</gtr:id><gtr:impact>Manned electrophoresis stand as demonstrator

Great interest and feedback from participants</gtr:impact><gtr:outcomeId>95A3B7AD8E1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DE94595A-8FDC-4FE6-BFB8-047EB0C7BEF9</gtr:id><gtr:impact>Large number of studentys came to the laboratory and carried out some simple experiments.

Considerable enthusiasm shown for the visit and good feedback from the schools.</gtr:impact><gtr:outcomeId>KfH5UaerXx6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>0DB1E77A-4D56-4A8E-B85F-D0AB615F400E</gtr:id><gtr:outcomeId>9E7E414F73E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A novel binding site in the NTD-of the AMPA receptor subunit GluR2 was discovered following a collaborative study with Dr Radu Aricescu of the Wellcome Center for Human Genetics, Oxford. Thgis followed the successful crystallization of the NTD.</gtr:description><gtr:grantRef>MC_U138162357</gtr:grantRef><gtr:id>EE7D3677-4F66-400C-B25B-DCCBA7D230C0</gtr:id><gtr:impact>The binding site offers a potential target for novel therapeutic drugs. This possibility is being pursued using funding from the MRC Gap Funding initiative.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>E890EC38E7D</gtr:outcomeId><gtr:patentId>NULL</gtr:patentId><gtr:protection>Protection not required</gtr:protection><gtr:title>Novel Binding site in GluR2 subunit</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2070920C-8DB9-4F71-A6DC-4B7939B97519</gtr:id><gtr:title>Actin-binding protein alpha-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15b5f023cd951dd68168cd5acfa59c9d"><gtr:id>15b5f023cd951dd68168cd5acfa59c9d</gtr:id><gtr:otherNames>Cabello N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>AC340FCA910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4383C02-D65E-4A6C-9E8A-47A0FBA095D1</gtr:id><gtr:title>N-Methyl-D-aspartate (NMDA) receptor subunit NR1 forms the substrate for oligomeric assembly of the NMDA receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fca51e4a642a6cee4284c20665681156"><gtr:id>fca51e4a642a6cee4284c20665681156</gtr:id><gtr:otherNames>Atlason PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>735A5A47F94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>435D9DAB-0D05-445E-BFE7-9357F201D064</gtr:id><gtr:title>Lateral diffusion of the GABAB receptor is regulated by the GABAB2 C terminus.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575e0a2595915220a4a67582c7d62d97"><gtr:id>575e0a2595915220a4a67582c7d62d97</gtr:id><gtr:otherNames>Pooler AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>AD0F0A06B9C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0614BA1-2719-45DF-953E-60C412D0DF05</gtr:id><gtr:title>SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe10ebdb8ef07071e879e1ba8081ed4"><gtr:id>0fe10ebdb8ef07071e879e1ba8081ed4</gtr:id><gtr:otherNames>Esapa CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>8DE4E14448A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ABADCE3-4A33-4167-8A40-2DF6DD6F58DE</gtr:id><gtr:title>The C-terminus of the metabotropic glutamate receptor 1b regulates dimerization of the receptor.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/268de182ecdf91bc5ffe993a45b58291"><gtr:id>268de182ecdf91bc5ffe993a45b58291</gtr:id><gtr:otherNames>Remelli R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>2B6CDA04DDF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C87FC206-9D8E-4FC6-B098-217A274E1583</gtr:id><gtr:title>Coordinated action of NSF and PKC regulates GABAB receptor signaling efficacy.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a380e932ecf2029b90a2beb15a62308"><gtr:id>6a380e932ecf2029b90a2beb15a62308</gtr:id><gtr:otherNames>Pontier SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>7D677B73650</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U138162357</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>